Welcome to HBW Insight
Create an account to read this article
Already a subscriber?
Sharfstein Takes “Acting” Title Literally, Starting FDA Overhaul
Before his first week on the job was over, FDA Acting Commissioner Josh Sharfstein made decisive moves on two fronts, quickly stepping up regulation and taking steps toward an overhaul of the agency's internal culture
More from Archive
• By
The US FTC’s contention that ‘notice and choice’ has failed as the cornerstone of consumer privacy regulation and must be abandoned in favor of data minimization and other more stringent measures does not adequately account for the complexity of business practices and consumer behavior, FTC commissioner Melissa Holyoak asserted at the NAD’s 2024 Annual Conference.
• By
FTC Commissioner Melissa Holyoak says the agency has acted outside the bounds afforded by Congress, citing several areas within consumer protection, including a recent update to the final rule for the Health Breach Notification Rule and the commission’s use of notices of penalty offense to serve as the basis for Section 5 settlements.
• By
At one year, TikTok Shop conjures the early days of Amazon, representing the ‘Wild West’ of beauty ecommerce, said co-founders of private label and contract manufacturing company KO-Pack at the IBA Cosmetics Convergence Fall 2024 Virtual Symposium, “The Promise and Pitfalls of TikTok Shop.”
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
More from HBW Insight
• By
Recent warning letters to seven companies marketing products with kratom extract known as 7-OH are FDA’s first in three years referencing unlawful products containing kratom and the first of all its kratom-related warnings to reference extracts from the botanical.
• By
Health Subcommittee will discuss reauthorizing OMUFA during a hearing on how to “maintain and improve” the public health workforce and rural health as well as access to OTC medicines.
• By
Middle-market beauty deals, which are defined as those with targets of $10m to $100m worth of enterprise value, are driving transaction momentum year-to-date that is in-line with levels during the same period last year, according to Capstone Partners’ Consumer Investment Banking Group.